PT828736E - Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase - Google Patents

Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase

Info

Publication number
PT828736E
PT828736E PT96917888T PT96917888T PT828736E PT 828736 E PT828736 E PT 828736E PT 96917888 T PT96917888 T PT 96917888T PT 96917888 T PT96917888 T PT 96917888T PT 828736 E PT828736 E PT 828736E
Authority
PT
Portugal
Prior art keywords
sulfonylphenylic
ciclooxigenase
heterocyclics
lipoxygenase inhibitors
lipoxygenase
Prior art date
Application number
PT96917888T
Other languages
English (en)
Inventor
John J Talley
James A Sikorski
Balekudru Devadas
Jeffery S Carter
Bryan H Norman
Hwang-Fun Lu
David L Brown
Roland S Rogers
Srinivasan Nagarajan
Matthew J Graneto
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23828245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT828736(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of PT828736E publication Critical patent/PT828736E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PT96917888T 1995-06-02 1996-05-31 Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase PT828736E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/460,324 US5643933A (en) 1995-06-02 1995-06-02 Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors

Publications (1)

Publication Number Publication Date
PT828736E true PT828736E (pt) 2003-12-31

Family

ID=23828245

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00100201T PT995747E (pt) 1995-06-02 1996-05-31 Heterociclos de sulfonilfenilo substituidos como inibidores de cicloxigenase-2 e 5-lipoxigenase
PT96917888T PT828736E (pt) 1995-06-02 1996-05-31 Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT00100201T PT995747E (pt) 1995-06-02 1996-05-31 Heterociclos de sulfonilfenilo substituidos como inibidores de cicloxigenase-2 e 5-lipoxigenase

Country Status (11)

Country Link
US (1) US5643933A (pt)
EP (2) EP0995747B1 (pt)
AT (2) ATE246188T1 (pt)
AU (1) AU6027996A (pt)
CA (1) CA2223091A1 (pt)
DE (2) DE69629290T2 (pt)
DK (2) DK0828736T3 (pt)
ES (2) ES2205035T3 (pt)
HK (1) HK1027802A1 (pt)
PT (2) PT995747E (pt)
WO (1) WO1996038442A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
DE69709069T2 (de) 1996-02-13 2002-07-04 Searle & Co Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
US6677364B2 (en) * 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EE04237B1 (et) * 1996-08-14 2004-02-16 G.D. Searle & Co. 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm, selle kasutamine ja valmistamise meetod
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
EP0971714B1 (en) * 1997-04-03 2002-10-09 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
US6127545A (en) * 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) * 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
TW492959B (en) * 1997-04-18 2002-07-01 Merck & Co Inc Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
IL132163A0 (en) * 1997-04-18 2001-03-19 Searle & Co Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
AU4428899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of cyclooxygenase-2
TW477789B (en) * 1998-09-03 2002-03-01 Japan Tobacco Inc Production method of oxazole compound
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ES2159479B1 (es) * 1999-10-25 2002-05-01 Menarini Lab Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
CA2482510A1 (en) * 2002-04-18 2003-10-30 Pharmacia Corporation Monotherapy for the treatment of parkinson`s disease with cyclooxygenase-2 (cox 2) inhibitor(s)
ES2375181T3 (es) 2002-05-09 2012-02-27 The Brigham And Women's Hospital, Inc. 1l 1rl-1 como un marcador de enfermedades cardiovasculares.
JP2005532333A (ja) * 2002-05-24 2005-10-27 ファルマシア・コーポレーション ジアリールピラゾールの合成
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
EP2266584B1 (en) * 2003-05-07 2012-09-05 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and/or treatment of cartilage and/or bone conditions
EP1534305B9 (en) * 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
EP3081214A3 (en) 2003-08-29 2016-11-16 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
WO2006042192A2 (en) 2004-10-06 2006-04-20 The Brigham And Womens's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
CA2626446A1 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
HUE056086T2 (hu) 2006-03-15 2022-01-28 Brigham & Womens Hospital Inc Gelszolin alkalmazása gyulladásos betegségek diagnosztizálására és kezelésére
EP2030025A2 (en) 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
ES2434215T3 (es) 2007-04-18 2013-12-16 Tethys Bioscience, Inc. Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
BRPI0814542A2 (pt) 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CN103037829A (zh) 2010-02-01 2013-04-10 儿童医院 用于治疗和预防再狭窄的远程缺血调节
CA2795053A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
WO2012095834A1 (en) * 2011-01-14 2012-07-19 Hal Allergy Holding B.V. Immunoassay for direct determination of antigen content of products comprising adjuvant-coupled-antigen particles
CA2873214C (en) 2012-05-11 2021-02-16 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
CN102839200B (zh) * 2012-05-25 2015-03-18 杭州师范大学 酶催化合成2,4,5-三取代的咪唑环类衍生物的方法
EA201590381A1 (ru) * 2012-08-16 2015-07-30 Янссен Фармацевтика Нв Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
MX2015010837A (es) 2013-02-20 2016-07-08 Basf Se Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242940A (en) * 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
GB8927287D0 (en) * 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5196419A (en) * 1989-02-28 1993-03-23 Imperial Chemical Industries Plc Heterocyclic cyclic ethers
US5234939A (en) * 1990-03-27 1993-08-10 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents
AU637500B2 (en) * 1990-06-21 1993-05-27 Zeneca Limited Bicyclic heterocyclic compounds
ATE134630T1 (de) * 1990-06-21 1996-03-15 Zeneca Ltd Bizyklische pyran-derivate und ihre verwendung als 5-lipoxygenasehemmer
GB9113137D0 (en) * 1990-07-13 1991-08-07 Ici Plc Thioxo heterocycles
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
US5308852A (en) * 1992-06-29 1994-05-03 Merck Frosst Canada, Inc. Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
ATE160345T1 (de) * 1993-01-15 1997-12-15 Searle & Co 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
AU6718494A (en) * 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
WO1995030669A1 (en) * 1994-05-06 1995-11-16 Zeneca Limited Ether derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK0828736T3 (da) 2003-11-24
DK0995747T3 (da) 2002-11-25
AU6027996A (en) 1996-12-18
ES2205035T3 (es) 2004-05-01
EP0995747B1 (en) 2002-08-07
DE69622894D1 (de) 2002-09-12
EP0828736A1 (en) 1998-03-18
EP0828736B1 (en) 2003-07-30
DE69629290T2 (de) 2004-04-22
EP0995747A1 (en) 2000-04-26
DE69622894T2 (de) 2003-04-30
HK1027802A1 (en) 2001-01-23
CA2223091A1 (en) 1996-12-05
US5643933A (en) 1997-07-01
WO1996038442A1 (en) 1996-12-05
ATE221885T1 (de) 2002-08-15
ES2181614T3 (es) 2003-03-01
DE69629290D1 (en) 2003-09-04
PT995747E (pt) 2002-12-31
ATE246188T1 (de) 2003-08-15

Similar Documents

Publication Publication Date Title
PT828736E (pt) Heterociclicos sulfonilfenilicos como inibidores de ciclooxigenase-2 e de 5-lipoxigenase
NO995544L (no) Forbindelser og metoder for inhibering av ekspresjonen av VCAM-1
PT863891E (pt) (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2
PT1254899E (pt) Derivados de piperazina e sua utilizacao como agentes anti-inflamatorios
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
NO20061736L (no) Krystallform av epotilon B
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69618820D1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EE9800230A (et) Difenüülstilbeenid kui COX-2 inhibiitorite eelravimid
BR9709264A (pt) Processo para produzir e composto
ATE355834T1 (de) Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung